Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 757-765

  Peeters, Monika ^a   Janssen, Katrien ^b   Kakuda, Thomas N ^c   Schöller Gyüre, Monika ^b   Lachaert, Ruth ^a   Hoetelmans, Richard M W ^a   Woodfall, Brian ^a   De Smedt, Goedele ^a  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec BVBA   (United States)

^c Tibotec Inc   (United States)

Author keywords

Electrocardiogram; Etravirine; QT interval; Safety; Tolerability

Indexed keywords

ETRAVIRINE; MOXIFLOXACIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; QT INTERVAL; RASH;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; QUINOLINES; SEX FACTORS;

EID: 44649109705     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K681     Document Type: Article

References (24)

1. Ludovici DW, De Corte BL, Kukla MJ, et al. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001;11:2235-9.
2. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2007 Feb 26).
3. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6.
4. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79:12773-82.
5. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve HIV-1 infected subjects. AIDS 2003;17:2487-94.
6. Gazzard B, Pozniak A, Rosenbaum W, et al. An open-label assessment of TMC125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17:49-54.
7. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007;370:29-38. DOI 10.1016/S0140-6736(07)61047-2
8. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo controlled trial. Lancet 2007;370:39-48. DOI 10.1016/S0140-6736(07)61048-4
9. Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS 2007;21:1648-51.
10. Busti AJ, Tiskouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006;7:317-22. DOI 10.1111/j.1468-1293.2006.00382.x
11. Chinello P, Petrosillo N. QT interval prolongation and antiretroviral treatment: another point of interest. Clin Infect Dis 2007;44:1388-9.
12. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsades de pointes. Am Heart J 2007;153:891-9. DOI 10.1016/j.ahj.2007.01.040
13. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline. J Clin Pharmacol 2006;46:498-507.
14. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Act Med Scand 1920;53:469-86.
15. Bazett HC. An analysis of the time-relationship of electrocardiograms. Heart 1920;70:353-70.
16. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol 1992;70:797-801.
17. Anson BD, Weaver JGR, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-6.
18. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. Ann Pharmacother 2002;36:1006-8. DOI 10.1345/aph.1A454
19. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66.
20. Intelence. [US] Prescribing information 2008. www.intelence-info.com/ intelence/full-product-info.html (accessed 2008 Feb 26).
21. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lechmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
22. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12:363-8.
23. Montaner J, Domingo P, Junod P, et al. Safety and tolerability of TMC125 in 3-class experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203. Presented at: 10th European AIDS Conference, Dublin, Ireland, October 17-20, 2005.
24. TMC125-C223 Writing Group: Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007;21:F1-10.